Gyurci John 4

What Happened

• John Gyurci (listed in the filing as Gyurci John), Vice President and Chief Accounting Officer of MiniMed Group, was granted two performance-based restricted stock unit awards on March 9, 2026: 2,778 RSUs and 25,253 RSUs, for a total of 28,031 RSUs. Each grant was recorded at $0.00 (award/grant), so the reported cash paid is $0; these are derivative awards contingent on performance and vesting conditions.

Key Details

• Transaction date: March 9, 2026. Transaction code: A (award/grant). Price per unit reported: $0.00.
• Total units granted: 2,778 + 25,253 = 28,031 performance-based RSUs. Reported value at grant: $0.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Notable footnotes:
  • F1: Each performance-based RSU is a contingent right to one share; vesting is subject to MMED common stock achieving a closing price of at least $32.05 as of the defined “Divestment Date.”
  • F2: Vesting occurs the later of March 9, 2027 or the Divestment Date.
  • F3: The filing also includes an option vesting schedule (33% on Mar 9, 2028 & Mar 9, 2029; 34% on Mar 9, 2030), though no option exercise was reported in these transactions.
• Filing timing: Report filed March 11, 2026 for a March 9, 2026 grant — appears to be a timely Form 4 filing (within the usual two-business-day window).

Context

• These were grants of performance-based RSUs (derivative awards), not open-market purchases or sales. The RSUs do not represent immediately transferable shares; they only convert into shares if and when performance and vesting conditions are met.
• Grants like this are typically part of executive compensation and do not necessarily indicate the insider buying or selling stock for personal investment reasons.